KRAS and familial pancreatic carcinoma: In pancreatic cancer, inactivation of oncogenic KRAS improves T cell infiltration; furthermore, combination therapy with KRAS inhibitors and immunotherapeutic agents improves responses and delays or prevents acquired resistance to KRAS inhibitors (28, 29).